Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain

Antiviral Therapy

Volumn 17, Issue 3, 2012, Pages 571-575

  Poveda, Eva ^a   Vispo, Eugenia ^a   Barreiro, Pablo ^a   De Mendoza, Carmen ^a   Labarga, Pablo ^a   Fernández Montero, JoséVicente ^a   Martin Carbonero, Luz ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ALLELE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTPATIENT DEPARTMENT; PREDICTION; PRIORITY JOURNAL; SPAIN;

ADULT; ANTIVIRAL AGENTS; COINFECTION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKINS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SPAIN; TREATMENT OUTCOME;

EID: 84856252248     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1992     Document Type: Article

References (45)

1. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of HCV infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002. (Pubitemid 41266795)
2. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. Hepatology 1999; 30:1054-1058. (Pubitemid 29458296)
3. Qurishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713. (Pubitemid 37468321)
4. Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011; 18:11-16.
5. The D:A:D Study. Liver-related deaths in persons infected with the HIV: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
6. Ruppik M, Ledergerber B, Rickenbach M, et al. Changing patterns of causes of death: SHCS, 2005 to 2009. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 789.
7. Soriano V, Zoulim F, Perelson A. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother 2008; 62:1-4. (Pubitemid 351865869)
8. Soriano V, Barreiro P, Martin-Carbonero L, et al. Update on the treatment of chronic hepatitis C in HIV-infected patients. AIDS Rev 2007; 9:99-113. (Pubitemid 47177082)
9. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55:245-264.
10. Poordad F, McCone J, Bacon B, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
11. Bacon BR, Gordon S, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
12. Jacobson I, McHutchison J, Dusheiko G, et al. Telaprevir combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients final results of Phase 3 ADVANCE study. 61st American Association for the Study of Liver Diseases. 30 October-2 November 2010, Boston, MA, USA. Abstract 211.
13. Sherman K, Flammm S, Afdhal N, et al. Telaprevir combination with peginterferon alfa-2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid virological response: final results of Phase 3 ILLUMINATE study. 61st American Association for the Study of Liver Diseases. 30 October-2 November 2010, Boston, MA, USA. Abstract LB-2.
14. Soriano V, Peters M, Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis 2009; 48:313-320.
15. Zeuzem S, Andreone P, Pol S, et al. REALIZE trial final results: telaprevir-based regimen for genotype 1 HCV infection in patients with prior null response, partial response or relapse to peginterferon/ribavirin. J Hepatol 2011; 54 Suppl 1:S3.
16. Sulkowski M, Bourliere M, Bronowicki J, et al. SILEN-C2: sustained virologic response and safety of BI-201335 combined with peginterferon alfa-2a and ribavirin (P/R) in chronic HCV genotype 1 patients with non-response to P/R. J Hepatol 2011; 54 Suppl 1:S30.
17. Zeuzem S, Foster G, Fried M, et al. The ASPIRE trial: TMC-435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous pegIFN/RBV treatment. J Hepatol 2011; 54 Suppl 1:S546.
18. McPhee F, Hernandez D, Yu F, et al. Characterization of virologic escape in HCV genotype 1 null responders receiving a combination of the NS3 protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052. J Hepatol 2011; 54 Suppl 1:S28-S29.
19. Poordad F, Bronowicki J-P, Gordon S, et al. IL28B polymorphisms predict virologic response in patients with hepatitis C genotype 1 treated with boceprevir combination therapy. J Hepatol 2011; 54 Suppl 1:S6.
20. Pol S, Aerssens J, Zeuzem S, et al. Similar SVR rates in IL28B CC, CT or TT prior relapsers, partial or null responder patients treated with telaprevir/peginterferon/ ribavirin: retrospective analysis of the REALIZE study. J Hepatol 2011; 54 Suppl 1:S6-S7.
21. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS ONE 2009; 4:e8209.
22. Ziol M, Handra-Luca A, Kettaneh A, et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41:48-54. (Pubitemid 40066382)
23. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350. (Pubitemid 40439195)
24. de Lédinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41:175-179.
25. Vergara S, Macías J, Rivero A, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C coinfection. Clin Infect Dis 2007; 45:969-974. (Pubitemid 47580344)
26. Kirk GD, Astemborski J, Mehta SH, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009; 48:963-972.
27. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 1999; 14:143-149. (Pubitemid 29095371)
28. Ge D, Fellay J, Thompson A, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
29. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
30. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
31. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
32. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure - a genome wide association study. Gastroenterology 2010; 138:1338-1345.e7.
33. Rallón NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24:F23-F29.
34. Maida I, Soriano V, Ramos B, Rios P, González-Lahoz J, Núñez M. Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference HIV centre. HIV Clin Trials 2005; 6:329-336. (Pubitemid 43336967)
35. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55:192-206.
36. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with HCV infection. Gastroenterology 2010; 138:447-462.
37. Zeuzem S, Asselah T, Angus P, et al. Strong antiviral activity and safety of INF-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127, and ribavirin, in patients with chronic hepatitis C: SOUND-C1 trial. 61st American Association for the Study of Liver Diseases. 30 October-2 November 2010, Boston, MA, USA. Abstract LB-7.
38. Gao M, Mettles R, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96-100.
39. Treviño A, de Mendoza C, Parra P, et al. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV coinfected patients. Antivir Ther 2011; 16:413-416.
40. Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009; 49:1069-1082.
41. Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010; 65:1079-1085.
42. Jiménez-Nácher I, Alvarez E, Morello J, Rodriguez-Nóvoa S, de Andrés S, Soriano V. Approaches for understanding and predicting drug interactions in HIV-infected patients. Expert Opin Drug Metab Toxicol 2011; 7:457-477.
43. Van Heeswijk R, Vandervoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 119.
44. Sulkowski M, Dietrich D, Sherman K, et al. Interim analysis of a Phase 2a double-blind study of TVR in combination with pegIFN-a2a and RBV in HIV/HCV co-infected patients. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 146LB.
45. Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical Pharmacology of BOC: Metabolism, excretion and drug-drug interactions. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 118.